{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T01:00:03Z","timestamp":1755219603940,"version":"3.43.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-025-04801-9","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T05:49:05Z","timestamp":1754545745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Model-informed drug repurposing of proton pump inhibitors for the prevention of oxaliplatin induced peripheral neuropathy: A real-world data analysis and pharmacometrics approach"],"prefix":"10.1007","volume":"95","author":[{"given":"Yasuhito","family":"Tsukushi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanade","family":"Koriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Kobuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukako","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Sakaeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"issue":"4","key":"4801_CR1","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","volume":"21","author":"C Cremolini","year":"2020","unstructured":"Cremolini C, Antoniotti C, Rossini D et al (2020) Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 21(4):497\u2013507. https:\/\/doi.org\/10.1016\/S1470-2045(19)30862-9","journal-title":"Lancet Oncol"},{"issue":"1","key":"4801_CR2","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12885-021-08031-z","volume":"21","author":"QP Janssen","year":"2021","unstructured":"Janssen QP, van Dam JL, Bonsing BA et al (2021) Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer 21(1):300. https:\/\/doi.org\/10.1186\/s12885-021-08031-z","journal-title":"BMC Cancer"},{"issue":"8","key":"4801_CR3","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(21)00297-7","volume":"22","author":"X Zhang","year":"2021","unstructured":"Zhang X, Liang H, Li Z et al (2021) Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol 22(8):1081\u20131092. https:\/\/doi.org\/10.1016\/S1470-2045(21)00297-7","journal-title":"Lancet Oncol"},{"issue":"4","key":"4801_CR4","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1080\/0284186X.2018.1556804","volume":"58","author":"LM Soveri","year":"2019","unstructured":"Soveri LM, Lamminm\u00e4ki A, H\u00e4nninen UA et al (2019) Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. Acta Oncol 58(4):398\u2013406. https:\/\/doi.org\/10.1080\/0284186X.2018.1556804","journal-title":"Acta Oncol"},{"issue":"16","key":"4801_CR5","doi-asserted-by":"publisher","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938\u20132947. https:\/\/doi.org\/10.1200\/JCO.2000.18.16.2938","journal-title":"J Clin Oncol"},{"issue":"29","key":"4801_CR6","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1200\/JCO.21.02628","volume":"40","author":"T Yoshino","year":"2022","unstructured":"Yoshino T, Oki E, Misumi T et al (2022) Final analysis of 3 versus 6 months of adjuvant oxaliplatin and Fluoropyrimidine-Based therapy in patients with stage III colon cancer: the randomized phase III ACHIEVE trial. J Clin Oncol 40(29):3419\u20133429. https:\/\/doi.org\/10.1200\/JCO.21.02628","journal-title":"J Clin Oncol"},{"issue":"1","key":"4801_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1111\/jns.12432","volume":"26","author":"G Wei","year":"2021","unstructured":"Wei G, Gu Z, Gu J et al (2021) Platinum accumulation in oxaliplatin-induced peripheral neuropathy. J Peripher Nerv Syst 26(1):35\u201342. https:\/\/doi.org\/10.1111\/jns.12432","journal-title":"J Peripher Nerv Syst"},{"issue":"2","key":"4801_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","volume":"9","author":"J Burgess","year":"2021","unstructured":"Burgess J, Ferdousi M, Gosal D et al (2021) Chemotherapy-Induced peripheral neuropathy: epidemiology, pathomechanisms and treatment. Oncol Ther 9(2):385\u2013450. https:\/\/doi.org\/10.1007\/s40487-021-00168-y","journal-title":"Oncol Ther"},{"issue":"2","key":"4801_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.21873\/anticanres.16846","volume":"44","author":"Y Tsukushi","year":"2024","unstructured":"Tsukushi Y, Kobuchi S, Ito Y, Sakaeda T (2024) Pharmacokinetic-toxicodynamic modeling to elucidate the involvement of dorsal root ganglion neuron in Oxaliplatin-induced peripheral neuropathy. Anticancer Res 44(2):575\u2013584. https:\/\/doi.org\/10.21873\/anticanres.16846","journal-title":"Anticancer Res"},{"key":"4801_CR10","doi-asserted-by":"publisher","first-page":"1159453","DOI":"10.3389\/fmed.2023.1159453","volume":"10","author":"M Ko","year":"2023","unstructured":"Ko M, Oh JM, Kim IW (2023) Drug repositioning prediction for psoriasis using the adverse event reporting database. Front Med (Lausanne) 10:1159453. https:\/\/doi.org\/10.3389\/fmed.2023.1159453","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"4801_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40001-023-01048-z","volume":"28","author":"Y Liu","year":"2023","unstructured":"Liu Y, Liu Y, Fan R et al (2023) Pharmacovigilance-based drug repurposing: searching for putative drugs with hypohidrosis or anhidrosis adverse events for use against hyperhidrosis. Eur J Med Res 28(1):95. https:\/\/doi.org\/10.1186\/s40001-023-01048-z","journal-title":"Eur J Med Res"},{"issue":"12","key":"4801_CR12","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3390\/ph13120480","volume":"13","author":"E Wakai","year":"2020","unstructured":"Wakai E, Suzumura Y, Ikemura K et al (2020) An integrated in Silico and in vivo approach to identify protective effects of palonosetron in Cisplatin-Induced nephrotoxicity. Pharmaceuticals (Basel) 13(12):480. https:\/\/doi.org\/10.3390\/ph13120480","journal-title":"Pharmaceuticals (Basel)"},{"issue":"12","key":"4801_CR13","doi-asserted-by":"publisher","first-page":"5613","DOI":"10.21873\/anticanres.16764","volume":"43","author":"A Kobayashi","year":"2023","unstructured":"Kobayashi A, Ikemura K, Wakai E et al (2023) Proton pump inhibitors ameliorate Oxaliplatin-induced peripheral neuropathy: retrospective analysis of two Real-world clinical databases. Anticancer Res 43(12):5613\u20135620. https:\/\/doi.org\/10.21873\/anticanres.16764","journal-title":"Anticancer Res"},{"issue":"8","key":"4801_CR14","doi-asserted-by":"publisher","first-page":"e44341","DOI":"10.7759\/cureus.44341","volume":"15","author":"M Begg","year":"2023","unstructured":"Begg M, Tarhuni M, N Fotso M et al (2023) Comparing the safety and efficacy of proton pump inhibitors and Histamine-2 receptor antagonists in the management of patients with peptic ulcer disease: A systematic review. Cureus 15(8):e44341. https:\/\/doi.org\/10.7759\/cureus.44341","journal-title":"Cureus"},{"issue":"10","key":"4801_CR15","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1007\/s10620-024-08593-5","volume":"69","author":"DM Simadibrata","year":"2024","unstructured":"Simadibrata DM, Lesmana E, Pratama MIA et al (2024) Vonoprazan vs. Proton pump inhibitors for treatment and prevention of gastric and\/or duodenal ulcers: A systematic review with Meta-Analysis. Dig Dis Sci 69(10):3863\u20133874. https:\/\/doi.org\/10.1007\/s10620-024-08593-5","journal-title":"Dig Dis Sci"},{"issue":"7","key":"4801_CR16","doi-asserted-by":"publisher","first-page":"e22163","DOI":"10.1371\/journal.pone.0022163","volume":"6","author":"AT Nies","year":"2011","unstructured":"Nies AT, Hofmann U, Resch C et al (2011) Proton pump inhibitors inhibit Metformin uptake by organic cation transporters (OCTs). PLoS ONE 6(7):e22163. https:\/\/doi.org\/10.1371\/journal.pone.0022163","journal-title":"PLoS ONE"},{"issue":"2\u20133","key":"4801_CR17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.cbi.2008.10.052","volume":"179","author":"L Pochini","year":"2009","unstructured":"Pochini L, Scalise M, Indiveri C (2009) Inactivation by Omeprazole of the carnitine transporter (OCTN2) reconstituted in liposomes. Chem Biol Interact 179(2\u20133):394\u2013401. https:\/\/doi.org\/10.1016\/j.cbi.2008.10.052","journal-title":"Chem Biol Interact"},{"issue":"8","key":"4801_CR18","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.21873\/anticanres.13581","volume":"39","author":"Y Ito","year":"2019","unstructured":"Ito Y, Kobuchi S, Takesada W, Takahashi C (2019) Assessment of Oxaliplatin-induced chronic neuropathy and anticancer efficacy through Pharmacokinetic and toxicodynamic evaluation of a rat model of colorectal cancer. Anticancer Res 39(8):4207\u20134213. https:\/\/doi.org\/10.21873\/anticanres.13581","journal-title":"Anticancer Res"},{"issue":"1","key":"4801_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/13880209.2019.1636828","volume":"57","author":"W Liu","year":"2019","unstructured":"Liu W, Liu G, Liu J (2019) Effects of Astragaloside IV on the pharmacokinetics of Omeprazole in rats. Pharm Biol 57(1):449\u2013452. https:\/\/doi.org\/10.1080\/13880209.2019.1636828","journal-title":"Pharm Biol"},{"issue":"6\u20137","key":"4801_CR20","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/jssc.200900590","volume":"33","author":"J De Smet","year":"2010","unstructured":"De Smet J, Boussery K, De Cock P et al (2010) A bio-analytical hydrophilic interaction LC-MS\/MS method for the simultaneous quantification of Omeprazole and Lansoprazole in human plasma in support of a Pharmacokinetic Omeprazole study in children. J Sep Sci 33(6\u20137):939\u2013947. https:\/\/doi.org\/10.1002\/jssc.200900590","journal-title":"J Sep Sci"},{"issue":"11","key":"4801_CR21","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1111\/bph.13482","volume":"173","author":"D Utsumi","year":"2016","unstructured":"Utsumi D, Matsumoto K, Amagase K et al (2016) 5-HT3 receptors promote colonic inflammation via activation of substance P\/neurokinin-1 receptors in dextran sulphate sodium-induced murine colitis. Br J Pharmacol 173(11):1835\u20131849. https:\/\/doi.org\/10.1111\/bph.13482","journal-title":"Br J Pharmacol"},{"issue":"10","key":"4801_CR22","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/psp4.12684","volume":"10","author":"JH Hughes","year":"2021","unstructured":"Hughes JH, Keizer RJ (2021) A hybrid machine learning\/pharmacokinetic approach outperforms maximum a posteriori bayesian Estimation by selectively flattening model priors. CPT Pharmacometrics Syst Pharmacol 10(10):1150\u20131160. https:\/\/doi.org\/10.1002\/psp4.12684","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"16","key":"4801_CR23","doi-asserted-by":"publisher","first-page":"8859","DOI":"10.3390\/ijms23168859","volume":"23","author":"K Mine","year":"2022","unstructured":"Mine K, Kawashiri T, Inoue M et al (2022) Omeprazole suppresses Oxaliplatin-Induced peripheral neuropathy in a rodent model and clinical database. Int J Mol Sci 23(16):8859. https:\/\/doi.org\/10.3390\/ijms23168859","journal-title":"Int J Mol Sci"},{"issue":"19","key":"4801_CR24","doi-asserted-by":"publisher","first-page":"11255","DOI":"10.3390\/ijms231911255","volume":"23","author":"ML Sheu","year":"2022","unstructured":"Sheu ML, Pan LY, Sheehan J et al (2022) Modulation of Aryl hydrocarbon receptor expression alleviated neuropathic pain in a chronic constriction nerve injury animal model. Int J Mol Sci 23(19):11255. https:\/\/doi.org\/10.3390\/ijms231911255","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4801_CR25","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/jnc.14607","volume":"148","author":"S Fujita","year":"2019","unstructured":"Fujita S, Hirota T, Sakiyama R et al (2019) Identification of drug transporters contributing to oxaliplatin-induced peripheral neuropathy. J Neurochem 148(3):373\u2013385. https:\/\/doi.org\/10.1111\/jnc.14607","journal-title":"J Neurochem"},{"issue":"9","key":"4801_CR26","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.3390\/ijms19092504","volume":"19","author":"L Juricek","year":"2018","unstructured":"Juricek L, Coumoul X (2018) The Aryl hydrocarbon receptor and the nervous system. Int J Mol Sci 19(9):2504. https:\/\/doi.org\/10.3390\/ijms19092504","journal-title":"Int J Mol Sci"},{"issue":"6","key":"4801_CR27","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2165\/00003088-200140060-00003","volume":"40","author":"T Andersson","year":"2001","unstructured":"Andersson T, Hassan-Alin M, Hasselgren G et al (2001) Pharmacokinetic studies with esomeprazole, the (S)-isomer of Omeprazole. Clin Pharmacokinet 40(6):411\u2013426. https:\/\/doi.org\/10.2165\/00003088-200140060-00003","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"4801_CR28","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1039\/c7mt00334j","volume":"10","author":"I Bu\u00df","year":"2018","unstructured":"Bu\u00df I, Hamacher A, Sarin N et al (2018) Relevance of copper transporter 1 and organic cation transporters 1\u20133 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics 10(3):414\u2013425. https:\/\/doi.org\/10.1039\/c7mt00334j","journal-title":"Metallomics"},{"issue":"11","key":"4801_CR29","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1124\/dmd.108.023168","volume":"36","author":"S Yokoo","year":"2008","unstructured":"Yokoo S, Masuda S, Yonezawa A et al (2008) Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab Dispos 36(11):2299\u20132306. https:\/\/doi.org\/10.1124\/dmd.108.023168","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"4801_CR30","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/00498254.2019.1601790","volume":"50","author":"S Kobuchi","year":"2020","unstructured":"Kobuchi S, Katsuyama Y, Ito Y (2020) Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of oxaliplatin for hematological toxicity in rats. Xenobiotica 50(2):223\u2013230. https:\/\/doi.org\/10.1080\/00498254.2019.1601790","journal-title":"Xenobiotica"},{"issue":"7","key":"4801_CR31","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.3390\/biomedicines12071414","volume":"12","author":"SP Ang","year":"2024","unstructured":"Ang SP, Chia JE, Valladares C (2024) Association between proton pump inhibitor use and risk of incident chronic kidney disease: systematic review and Meta-Analysis. Biomedicines 12(7):1414. https:\/\/doi.org\/10.3390\/biomedicines12071414","journal-title":"Biomedicines"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04801-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04801-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04801-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T05:49:06Z","timestamp":1754545746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04801-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4801"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04801-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All of the animal experiments were approved by the Institutional Animal Care and Use Committee (No. A22-051), and conducted in accordance with the Kyoto Pharmaceutical University Animal Experimentation Guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"79"}}